Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Coleman

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Microbiology|August 16, 2011
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitorsKen Coleman
Scientific American|June 5, 2010
Fake botox, real threatKen Coleman, Raymond A Zilinskas
Health Security|November 18, 2016
Hitting a Moving Target: A Strategic Tool for Analyzing Terrorist ThreatsKen Coleman, Noriko Ishisoko, Milana Trounce, et al.
Antimicrobial Agents and Chemotherapy|January 14, 2015
In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamasesPremavathy Levasseur, Anne-Marie Girard, Christine Miossec, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2014
Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic modelKen Coleman, Premavathy Levasseur, Anne-Marie Girard, et al.
Antimicrobial Agents and Chemotherapy|May 22, 2013
Potentiation of azole antifungals by 2-adamantanamineMichael D Lafleur, Lingmei Sun, Ida Lister, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2014
In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pyloriEkaterina Gavrish, Binu Shrestha, Chao Chen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Microbiology|August 16, 2011
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitorsKen Coleman
Scientific American|June 5, 2010
Fake botox, real threatKen Coleman, Raymond A Zilinskas
Health Security|November 18, 2016
Hitting a Moving Target: A Strategic Tool for Analyzing Terrorist ThreatsKen Coleman, Noriko Ishisoko, Milana Trounce, et al.
Antimicrobial Agents and Chemotherapy|January 14, 2015
In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamasesPremavathy Levasseur, Anne-Marie Girard, Christine Miossec, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2014
Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic modelKen Coleman, Premavathy Levasseur, Anne-Marie Girard, et al.
Antimicrobial Agents and Chemotherapy|May 22, 2013
Potentiation of azole antifungals by 2-adamantanamineMichael D Lafleur, Lingmei Sun, Ida Lister, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2014
In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pyloriEkaterina Gavrish, Binu Shrestha, Chao Chen, et al.
Pageof 1